Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Adverum... Read More

REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum’s 2017 Inducement Plan. These... Read More

REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. “We believe Ixo-vec is poised to... Read More

REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the award... Read More

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside... Read More

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMD Non-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve... Read More

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,380 shares of common stock and restricted stock units (RSUs) for 22,790 shares of common stock to 5 new employees under Adverum’s 2017 Inducement Plan. The... Read More

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET. The webcast of the presentation may be accessed under... Read More

REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, at 4:40 p.m. ET. The webcast of the presentation may be accessed... Read More

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on December 4, 2024, the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 68,640 shares of common stock and restricted stock units (RSUs) for 34,920 shares of common stock to 13 new employees under Adverum’s 2017... Read More

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of... Read More

52-week LUNA data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec 6E10 dose in LUNA maintains visual and anatomic endpoints and demonstrates potential best-in-class injection-free rates and reduction in injection burden No LUNA patients who received local steroid prophylaxis had inflammation at week 52 or at any subsequent visit, and 100% of OPTIC... Read More

Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, plans to host a webcast to report 52-week LUNA phase 2 clinical data and 4-year OPTIC... Read More

52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 Appointed Jason Mitchell as chief commercial officer On track to initiate pivotal program in 1H 2025 $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a... Read More

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the... Read More

REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 12,660 shares of common stock and restricted stock units (RSUs) for 6,330 shares of common stock to 3 new employees under Adverum’s 2017... Read More

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc . (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: H.C. Wainwright 26 th Annual Global Investment Conference on Tuesday, September 10 th at 3:30 p.m. ET.... Read More

6E10 dose of Ixo-vec selected for Phase 3 pivotal trials LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 $173.8 million in cash, cash equivalents and short-term investments expected to fund... Read More

REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at the H.C. Wainwright 4 th Annual Ophthalmology Virtual... Read More

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Ixo-vec, its clinical-stage gene therapy product candidate, for... Read More

6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled... Read More

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet... Read More

REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at TD Cowen’s Genetic Medicines & RNA Summit on Friday,... Read More

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company’s executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company’s Board of Directors. Dr. Ozden has... Read More

Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for... Read More

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET. BofA Securities 2024 Health... Read More

REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related... Read More

Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD Completed $127.5 million private placement financing with new and existing institutional investors Cash runway expected into late 2025 1-for-10 reverse stock split to be effective March 21, 2024 REDWOOD CITY, Calif., March 18, 2024 (GLOBE... Read More

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44 th... Read More

REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on... Read More

Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints Preliminary safety data support a favorable benefit-risk profile at both dose levels Ozurdex + difluprednate identified as potential “go-forward” prophylaxis The vast majority of patients on the “go-forward” regimen had... Read More

Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well two large investment management firms. Pro forma cash and investments expected to fund current operating plan into late 2025. REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Adverum... Read More

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new... Read More

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer. Dr. Corbau will serve as a member of Adverum’s executive committee. “On behalf of the... Read More

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47 th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. “We are very... Read More

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6 th... Read More

Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up Initial Phase 2 LUNA efficacy and... Read More

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical... Read More

Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 Durable aflibercept protein levels up to 4.5 years after a single... Read More

Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range Ixo-vec has been well tolerated with a favorable preliminary safety profile Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 REDWOOD CITY,... Read More

REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc . (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 8:00... Read More

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023.... Read More

REDWOOD CITY, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s chief technology officer. Dr. Ramelmeier will serve as a member of Adverum’s executive committee and will... Read More

REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 3 rd Annual Ophthalmology Virtual Conference on... Read More

LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 Combined OPTIC and LUNA trials will follow approximately 90 wet AMD subjects dosed with Ixo-vec out to five years to inform global pivotal trials Cash runway projected into 2025 REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Adverum... Read More

REDWOOD CITY, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announces an agreement granting Ray Therapeutics a non-exclusive, royalty bearing license of Adverum’s proprietary AAV.7m8 intravitreal (IVT) vector capsid to be used in conjunction with Ray’s... Read More

REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York, New York. The... Read More

Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor Star Seyedkazemi, Pharm.D., chief development officer, expands her responsibilities to lead Adverum’s clinical development, medical affairs and pharmacovigilance teams REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new... Read More

REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting... Read More

Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 IVT administration of AAV-CFI using either the 7m8 or LSV1 capsid resulted in high expression levels and was well tolerated in non-human primates (NHPs) Presented data on an optogenetics program utilizing an engineered melanopsin mutant... Read More

Full enrollment of the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD) is anticipated in the second half of 2023 LUNA 14-week data, including initial aflibercept protein levels anticipated in the third quarter 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a... Read More

REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that members of the executive team will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference being held on Wednesday, May 17, 2023 at 3:35 p.m. ET... Read More

REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data will be presented during the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting being held May 16-20, 2023, in Los Angeles, California. At ASGCT 2023, Adverum... Read More

Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in the primary eye Staggered administration of Ixo-vec in non-human primates (NHPs) showed peak aflibercept protein levels in the second eye within the targeted therapeutic range, supporting the potential for bilateral... Read More

Innovative Licensing and Access Pathway designation is intended to accelerate the regulatory review process in the United Kingdom Ixo-vec has also been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) REDWOOD CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a... Read More

REDWOOD CITY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present an abstract featuring nonclinical data of Ixoberogene soroparvovec (Ixo-vec) for the treatment of neovascular age-related macular degeneration at the... Read More

Full enrollment of the LUNA trial anticipated in the second half of 2023 LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023 Cash runway into 2025 REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) - - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene... Read More

REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences: Cowen 43 rd Annual Health Care... Read More

REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc . (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On January 17, 2023, Adverum granted a new employee a stock option to purchase 150,000 shares of Adverum’s common stock pursuant to the inducement... Read More